The metabolic syndrome in schizophrenia: is inflammation a contributing cause
Journal of Psychopharmacology,  Clinical Article

Leonard BE et al. – The effects of inflammatory mediators on the brain causally contribute to the pathology of schizophrenia and the ill health that accompanies the disorder.

  • The impact of prenatal infections on the developing brain, the possible genetic link between the human lymphocyte antigen gene, inflammation, heart disease and diabetes, together with the increase in pro-inflammatory cytokines in the blood and cerebrospinal fluid provide convincing evidence that inflammation is a major factor in the pathology of this disorder.
  • The changes in immune-related markers and specific neurotransmitters associated with the positive symptoms of schizophrenia are described.
  • In addition, the possible mechanism whereby structural changes occur in the brain is associated with the neurotoxic effects of pro-inflammatory cytokines, together with the neurotoxic metabolites from the tryptophan–kynurenine pathway that is activated by pro-inflammatory cytokines, is also discussed.
  • The role of effective antipsychotic drug treatment in attenuating the inflammatory response is described.
  • However, evidence is limited regarding the causal connection between atypical antipsychotic drugs and the changes in glucose and lipid metabolism that could trigger the onset of physical ill health, including diabetes and heart disease.
  • Indeed, there is evidence that there is a metabolic predisposition to diabetes in patients with schizophrenia that is exacerbated by obesity and thereby contributes to cardiovascular disease and other co-morbid illnesses.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Psychiatry

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Psychiatry Articles

1 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

2 Vascular Endothelial Growth Factor: A potential diagnostic biomarker for major depression Journal of Psychiatric Research, September 19, 2014    Clinical Article

3 Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials JAMA Psychiatry, October 22, 2014    Evidence Based Medicine    Clinical Article

4 Comparative efficacy and acceptability of drug treatments for bipolar depression: A multiple-treatments meta-analysis Acta Psychiatrica Scandinavica, October 10, 2014    Evidence Based Medicine    Clinical Article

5 Antidepressants and the risk of hyponatraemia: A class-by-class review of the literature Psychosomatics, September 15, 2014    Review Article

6 Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis Schizophrenia Research, September 24, 2014    Clinical Article

7 Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls Bipolar Disorders, October 3, 2014    Clinical Article

8 Diffusion tensor imaging predictors of treatment outcomes in major depressive disorder The British Journal of Psychiatry, October 8, 2014    Clinical Article

9 A comparison between phone-based psychotherapy with and without text messaging support in between sessions for crisis patients Full Text Journal of Medical Internet Research, October 13, 2014    Free full text    Clinical Article

10 Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression International Journal of Neuropsychopharmacology, October 2, 2014    Clinical Article

11 Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine Journal of Psychopharmacology, October 16, 2014    Clinical Article

12 Cognitive improvement of attention and inhibition in the late afternoon in children with attention-deficit hyperactivity disorder (ADHD) treated with osmotic-release oral system methylphenidate Journal of Child Neurology, October 15, 2014    Clinical Article

13 Prazosin in the treatment of PTSD Journal of Psychiatric Practice, July 25, 2014    Review Article

14 Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis European Neuropsychopharmacology, September 2, 2014    Evidence Based Medicine    Review Article

15 Attention-deficit/hyperactivity disorder and adverse health outcomes in adults The Journal of Nervous and Mental Disease, October 29, 2014    Clinical Article

16 Therapist-assisted Internet–delivered Cognitive Behavior Therapy for depression and anxiety: Translating evidence into clinical practice Journal of Anxiety Disorders, October 17, 2014    Clinical Article

17 Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia American Journal of Psychiatry, October 6, 2014    Evidence Based Medicine    Clinical Article

18 Internet-delivered exposure-based cognitive-behavioural therapy and behavioural stress management for severe health anxiety: Randomised controlled trial The British Journal of Psychiatry, October 14, 2014    Clinical Article

19 Psychiatric correlates of alcohol and tobacco use disorders in U.S. adults aged 65 years and older: Results from the 2001-2002 National Epidemiologic Survey of Alcohol and Related Conditions The American Journal of Geriatric Psychiatry, October 9, 2014    Clinical Article

20 Cigarette smoking and the onset and persistence of depression among adults in the United States: 1994-2005 Comprehensive Psychiatry, October 28, 2014    Clinical Article

Indexed Journals in Psychiatry : Current Psychiatry, Bipolar Disorders, American Journal of Psychiatry, Addictionmore